Short answer
Biohaven Ltd. (BHVN) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$129M
- +25.5% YoY · +5.8% QoQ
- EPS (diluted)
- −$0.85
- +47.9% YoY · +7.6% QoQ
Source: XBRL data from the Biohaven Ltd. (BHVN) Q3 2026 10-Q on SEC EDGAR. USD.
Biohaven Ltd. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, with no product sales
- Net loss $129.3M vs $173.4M YoY, operating margin not meaningful due to no revenue
- Highest R&D spend: BHV-1400 at $10.1M, lowest: BHV-2100 and BHV-2110 at $(1.2)M
- Cash and equivalents $95.8M plus marketable securities $65.4M; operating cash use $341.9M year-to-date
- Outlook: RISE 3 topline results on track for second half of 2026; BHV-7000 enrollment paused under partial clinical hold
Risk Factors
- New Ono collaboration risk: October 2026 license covers MoDE™ degraders in Japan, South Korea, Taiwan, and ASEAN
- Most materially updated financial risk: no committed external funding beyond potential SKBP and Ono payments
- Regulatory and compliance risk: SKBP HSR waiting period expired October 28, 2026, but remaining closing conditions persist
- Operational risk: SKBP controls development resources for Kv7 products, including opakalim
- Financial risk: SKBP agreement includes $400.0 million upfront and up to $150.0 million milestone payments at risk
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Biohaven Ltd. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.